Indicatie
Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
In andere landen
Dezelfde werkzame stoffen in andere registers, met hetzelfde merk eerst.
Nationale vermeldingen
De nationale registers waarin dit EU-geneesmiddel staat.
- JINARC 15 mg + 45 mg COMPRIMIDOSSpanje · 45 mg + 15 mgToegelaten
- JINARC 15 mg + 45 mg COMPRIMIDOSSpanje · 45 mg + 15 mgIn de handel
- JINARC 15 mg COMPRIMIDOSSpanje · 15 mgIn de handel
- JINARC 30 mg + 60 mg comprimidosSpanje · 60 mg + 30 mgIn de handel
- JINARC 30 mg + 60 mg COMPRIMIDOSSpanje · 60 mg + 30 mgToegelaten